Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EGM and posting of Circular to Shareholders

7 Nov 2014 11:49

RNS Number : 4700W
3Legs Resources plc
07 November 2014
 



 

7 November 2014

 

 

3Legs Resources plc

 

3Legs Resources plc ("3Legs" or the "Company") announces details of an Extraordinary General Meeting and the posting of a Circular to Shareholders

 

 

3Legs announces that it has today posted a circular (the "Circular") to shareholders convening an extraordinary general meeting of the Company (the "Extraordinary General Meeting") to seek approval for a proposed interim return of capital to shareholders (the "Capital Return") and the adoption of an investing policy for the purposes of Rule 15 of the AIM Rules for Companies (the "AIM Rules").

 

In its Interim Report published on 30 September 2014, the Company announced its intention, in the absence of a suitable alternative course of action, to return its remaining funds, net of windup costs, to shareholders and to place itself into solvent liquidation. This announcement followed the Company's decision to withdraw from its principal exploration project in Poland's Baltic Basin and to terminate its other exploration activities.

 

Since publishing its Interim Report, the Company announced on 3 November 2014 the sale of its eastern Baltic Basin concessions to Stena AB for €500,000. The Company has also been refunded its share of excess cash calls due from the joint venture vehicle Lane Energy Poland Sp. z o.o., as planned. The Company continues to pursue a claim against ConocoPhillips for the return of its 30 per cent. share of a working capital surplus accumulated in the joint venture vehicle since September 2012. The value of this claim is US$1.64 million net.

 

On 22 October and 3 November 2014, the Company issued new Ordinary Shares following the exercise of share options. A total of 1,143,388 new Ordinary shares were issued, at an exercise price of US$0.2075 per Ordinary Share, taking the Company's issued share capital to 86,126,729 Ordinary Shares.

 

As at 5 November 2014, the Company held cash resources of approximately £17.5 million. The Company estimates the costs of the disposal and/or winding up of its remaining subsidiaries (including staff redundancy costs) at approximately £0.6 million. Allowing a further £0.9 million for contingencies, the Company now proposes to make an interim return of capital of approximately £15.9 million (subject to the Board being satisfied as to the Company's solvency position immediately following the Extraordinary General Meeting and the making of the Capital Return) equivalent to 18.5 pence per Ordinary Share, as further described in the Circular. In order to be entitled to receive a payment under the Capital Return, a shareholder must be registered on the register of members of the Company at 6.00 p.m. on 25 November 2014 (a "Qualifying Shareholder"). Capital Return payments are intended to be made to Qualifying Shareholders on 2 December 2014. Following completion of the Capital Return and in the absence of a suitable alternative course of action, the Company intends to put itself into a members' voluntary liquidation as soon as possible, and in any event by 31 March 2015, to be followed by a final distribution to be made at the conclusion of the liquidation.

 

As a result of the transactions referred to above, the Company is now deemed an 'investing company' under Rule 15 of the AIM Rules. Consequently, the Company is required to publish an investing policy (as defined in the AIM Rules) and to obtain shareholder consent for that policy. The Company's proposed Investing Policy (the "Investing Policy") for the purposes of Rule 15 of the AIM Rules is as follows: following the Capital Return, the Company intends to put itself into a members' voluntary liquidation as soon as possible, and in any event by 31 March 2015, to be followed by a final distribution to be made at the conclusion of the liquidation. Following approval of the Investing Policy, the Company will not depart in any material respect from its Investing Policy without seeking approval from its shareholders. The Company would need either to implement, to the satisfaction of the London Stock Exchange, the Investing Policy or to make an acquisition or acquisitions which constitute a reverse takeover under Rule 14 of the AIM Rules, in either case, within 12 months of the Company becoming an investing company, in order to avoid suspension of its Ordinary Shares from trading on AIM.

 

The adoption by the Company of the Investing Policy and the Capital Return are both subject to the approval of shareholders at the Extraordinary General Meeting. The resolution to approve the adoption of the Investing Policy (being an ordinary resolution) and the resolution to approve the Capital Return (being a special resolution) (together, the "Resolutions") are set out in the notice of Extraordinary General Meeting included in the Circular (the "Notice"). The Extraordinary General Meeting is to be held at The Claremont Hotel, 18-22 Loch Promenade, Douglas, Isle of Man, IM1 2LX at 11.00 a.m. on 25 November 2014.

 

The Directors of 3Legs consider that the adoption of the Investing Policy and the Capital Return are in the best interests of the Company and the shareholders as a whole. Accordingly, the Directors unanimously recommend all shareholders to vote in favour of the Resolutions at the Extraordinary General Meeting, as the Directors intend to do in respect of their entire beneficial holdings in the Company's shares.

 

The Circular and Notice are available to view on the Company's website (www.3legsresources.com).

 

The times and dates referred to above may be subject to change, in which case the Company will give notice of such change by issuing a further announcement.

 

For further information contact:

 

3Legs Resources plc

Tel:

+44 1624 811 611

Kamlesh Parmar, Chief Executive Officer

Alexander Fraser, Chief Financial Officer

Jefferies Hoare Govett

Tel:

+44 207 029 8000

Simon Hardy

Graham Hertrich

Northland Capital Partners

Tel:

+44 207 382 1100

Matthew Johnson

FTI Consulting

Tel:

+44 203 727 1000

Oliver Winters

Shannon Brushe

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQKODQDBDDFDK
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.